2. Search Result
Search Result
Results for "

antiangiogenic

" in MedChemExpress (MCE) Product Catalog:

381

Inhibitors & Agonists

2

Biochemical Assay Reagents

44

Peptides

18

Inhibitory Antibodies

88

Natural
Products

1

Recombinant Proteins

22

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10331
    Regorafenib
    85+ Cited Publications

    BAY 73-4506

    		 VEGFR Autophagy PDGFR Raf RET c-Kit FGFR Tie Cancer
    Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity .
    Regorafenib
  • HY-13016
    Cabozantinib
    55+ Cited Publications

    XL184; BMS-907351

    		 VEGFR c-Met/HGFR c-Kit TAM Receptor FLT3 Apoptosis Cancer
    Cabozantinib is a potent and orally active inhibitor of VEGFR2 and MET, with IC50 values of 0.035, and 1.3 nM, respectively. Cabozantinib displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC50=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib shows antiangiogenic activity. Cabozantinib disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis .
    Cabozantinib
  • HY-12289
    Defactinib
    55+ Cited Publications

    VS-6063; PF-04554878

    		 FAK Cancer
    Defactinib (VS-6063; PF-04554878) is a novel FAK inhibitor with potential antiangiogenic and antineoplastic activities.
    Defactinib
  • HY-17514
    Itraconazole
    20+ Cited Publications

    R51211

    		 Fungal Hedgehog Cytochrome P450 Autophagy Antibiotic Bacterial Infection Cancer
    Itraconazole (R51211) is a triazole antifungal agent and a potent and orally active Hedgehog (Hh) signaling pathway antagonist with an IC50 of ~800 nM. Itraconazole potently inhibits lanosterol 14α-demethylase (cytochrome P450 enzyme), thereby inhibits the oxidative conversion of lanosterol to ergosterol. Itraconazole has anticancer and antiangiogenic effects. Itraconazole is a oxysterol-binding protein (OSBP) inhibitor .
    Itraconazole
  • HY-B0639
    Amifostine
    10+ Cited Publications

    WR2721

    		 MDM-2/p53 HIF/HIF Prolyl-Hydroxylase Cancer
    Amifostine (WR2721) is a broad-spectrum cytoprotective agent and a radioprotector. Amifostine selectively protects normal tissues from damage caused by radiation and chemotherapy. Amifostine is potent hypoxia-inducible factor-α1 (HIF-α1) and p53 inducer. Amifostine protects cells from damage by scavenging oxygen-derived free radicals. Amifostine reduces renal toxicity and has antiangiogenic action .
    Amifostine
  • HY-B0421
    Mycophenolic acid
    10+ Cited Publications

    Mycophenolate

    		 Dengue Virus Apoptosis Bacterial Fungal Endogenous Metabolite Antibiotic Flavivirus Infection Inflammation/Immunology Cancer
    Mycophenolic acid is a potent uncompetitive inosine monophosphate dehydrogenase (IMPDH) inhibitor with an EC50 of 0.24 µM. Mycophenolic acid demonstrates antiviral effects against a wide range of RNA viruses including influenza. Mycophenolic acid is an immunosuppressive agent. Antiangiogenic and antitumor effects .
    Mycophenolic acid
  • HY-164388
    Z-VAD
    Maximum Cited Publications
    19 Publications Verification

    		 Caspase Apoptosis Autophagy Necroptosis Cardiovascular Disease Cancer
    Z-VAD is an irreversible, broad-spectrum pan-caspase inhibitor that can inhibit a variety of caspases including caspase-3, -6, -7, -8, -9, etc. (with a weaker inhibitory effect on caspase-2). Z-VAD can block apoptosis signaling pathways, induce autophagy and necrosis in tumor cells, and has anti-angiogenic activity. Z-VAD can enhance the sensitivity of breast cancer and lung cancer cells to radiotherapy in vitro and in vivo, and prolong the growth delay of tumor xenograft models. Z-VAD is well tolerated and is mainly used in research related to cancer radiosensitization and cell death pathway regulation .
    Z-VAD
  • HY-10454
    Delanzomib
    4 Publications Verification

    CEP-18770

    		 Proteasome NF-κB Apoptosis Cancer
    Delanzomib (CEP-18770) is a potent and orally active chymotrypsin-like activity of the proteasome inhibitor with an IC50 of 3.8 nM. Delanzomib inhibits NF-κB activity, induces cancer cell apoptotic, and has strong antiangiogenic and anti-cancer activities .
    Delanzomib
  • HY-P99330
    Vanucizumab

    Anti-Human VEGFA Recombinant Antibody; RO5520985

    		 VEGFR Tie Cancer
    Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects .
    Vanucizumab
  • HY-B1074
    Ethamsylate

    Etamsylate

    		 Prostaglandin Receptor Cardiovascular Disease Endocrinology
    Ethamsylate (Etamsylate) is an orally active anti-hemorrhagic compound. Ethamsylate inhibits biosynthesis and action of prostaglandins. Ethamsylate has the potential to maintain early hemostasis as well as restores capillary resistance. Ethamsylate acts as an antiangiogenic factor, inhibiting wound healing and matrigel tubulogenesis. .
    Ethamsylate
  • HY-112151
    EG01377
    5 Publications Verification

    		 Complement System Cancer
    EG01377 is a potent, bioavailable and selective inhibitor of neuropilin-1 (NRP1), with a Kd of 1.32 μM, and IC50s of both 609 nM for NRP1-a1 and NRP1-b1. EG01377 has antiangiogenic, antimigratory, and antitumor effects .
    EG01377
  • HY-10331A
    Regorafenib monohydrate
    85+ Cited Publications

    BAY 73-4506 monohydrate

    		 VEGFR Autophagy PDGFR Raf RET FGFR c-Kit Tie Cancer
    Regorafenib (BAY 73-4506) monohydrate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib monohydrate shows very robust antitumor and antiangiogenic activity .
    Regorafenib monohydrate
  • HY-W013478
    PTP inhibitor 1

    		Phosphatase Cancer
    PTP inhibitor 1 is a protein tyrosine phosphatase (PTP) inhibitor, with anti-angiogenic effect .
    PTP inhibitor 1
  • HY-N2229
    Rhapontigenin
    3 Publications Verification

    		 Cytochrome P450 Fungal Bacterial Infection Inflammation/Immunology Cancer
    Rhapontigenin is a natural analog of resveratrol with anticancer, antioxidant, antifungal and antibacterial activities. Rhapontigenin is amechanism-based, potent and selective cytochrome P450 1A1 inactivator (IC50  = 400 nM). Rhapontigenin exhibits 400-fold and 23-fold selectivity for P450 1A1 over P450 1A2 and P450 1B1, respectively .
    Rhapontigenin
  • HY-112151A
    EG01377 dihydrochloride
    5 Publications Verification

    		 Complement System Cancer
    EG01377 dihydrochloride is a potent, bioavailable and selective inhibitor of neuropilin-1 (NRP1), with a Kd of 1.32 μM, and IC50s of 609 nM for both NRP1-a1 and NRP1-b1. EG01377 dihydrochloride has antiangiogenic, antimigratory, and antitumor effects .
    EG01377 dihydrochloride
  • HY-118530
    Bucillamine
    2 Publications Verification

    SA96; Thiobutarit

    		 VEGFR Cardiovascular Disease Inflammation/Immunology
    Bucillamine (SA96) is an orally active and potent sulfhydryl donor and antioxidant. Bucillamine is also an antirheumatic agent with antiangiogenic properties. Bucillamine can protect against Ischemia/reperfusion (I/R) injury in high-risk organ transplants. Bucillamine inhibits the production of VEGF. Bucillamine can be used for the research of choroidal neovascularization (CNV) and rheumatoid arthritis (RA) .
    Bucillamine
  • HY-N9396
    Nasunin
    1 Publications Verification

    Delphinidin-3-(p-coumaroylrutinoside)-5-glucoside

    		 NF-κB Metabolic Disease Inflammation/Immunology
    Nasunin, an antioxidant anthocyanin, possesses antiangiogenic activity .
    Nasunin
  • HY-P99296
    Intetumumab

    CNTO 95; Anti-Human CD51 Recombinant Antibody

    		 Integrin Apoptosis Cancer
    Intetumumab (CNTO 95) is a human monoclonal antibody targeting αv integrin, with a Kd value of 1-24 nM. Through high-affinity binding to αv integrin, Intetumumab inhibits its interaction with extracellular matrix proteins (such as vitronectin and fibronectin), thereby blocking the downstream focal adhesion kinase signaling pathway. This further inhibits the adhesion, migration and invasion of tumor cells as well as the proliferation of vascular endothelial cells, promotes cell apoptosis, and exerts anti-tumor and anti-angiogenic effects. Intetumumab can be used in research related to head and neck cancer, non-small cell lung cancer and uterine serous papillary carcinoma .
    Intetumumab
  • HY-17601
    Alofanib
    4 Publications Verification

    RPT835

    		 FGFR Apoptosis Cardiovascular Disease Cancer
    Alofanib (RPT835) is a potent and selective allosteric inhibitor of fibroblast growth factor receptor 2 (FGFR2). Anticancer and antiangiogenic activity .
    Alofanib
  • HY-P99768
    Olinvacimab

    TTAC-0001; Tanibirumab

    		 VEGFR Cancer
    Olinvacimab (TTAC-0001) is a fully human anti-VEGFR2 monoclonal antibody. Olinvacimab inhibits VEGF binds to KDR with a Kd value of 0.23 nM. Olinvacimab has antiangiogenic activity. Olinvacimab can be used for the research of recurrent glioblastoma and breast cancer .
    Olinvacimab
  • HY-19986
    AAL993

    		VEGFR Cardiovascular Disease Cancer
    IC50s of 130 nM, 23 nM, and 18 nM for VEGFR1, VEGFR2, and VEGFR3, respectively. AAL993 shows less potently inhibits other tyrosine kinases. AAL993 possesses potent antiangiogenic and antitumor properties .
    AAL993
  • HY-B0421A
    Mycophenolic acid sodium
    10+ Cited Publications

    Mycophenolate sodium

    		 Dengue Virus Apoptosis Bacterial Fungal Antibiotic Endogenous Metabolite Flavivirus Infection Inflammation/Immunology Cancer
    Mycophenolic acid sodium is a potent uncompetitive inosine monophosphate dehydrogenase (IMPDH) inhibitor with an EC50 of 0.24 µM. Mycophenolic acid sodium demonstrates antiviral effects against a wide range of RNA viruses including influenza. Mycophenolic acid sodium is an immunosuppressive agent. Antiangiogenic and antitumor effects .
    Mycophenolic acid sodium
  • HY-P5910
    Azurin p28 peptide

    		MDM-2/p53 Apoptosis Cancer
    Azurin p28 peptide is a tumor-penetrated antitumor peptide. Azurin p28 peptide redues proteasomal degradation of p53 through formation of a p28: p53 complex. Azurin p28 peptide induces apoptosis or cell cycle arrest. Azurin p28 peptide inhibits p53-positive tumor growths. Azurin p28 peptide shows antiangiogenic effect by inhibiting phosphorylation of VEGFR-2, FAK and Akt .
    Azurin p28 peptide
  • HY-115452
    G5-7

    		JAK Apoptosis Cancer
    G5-7, an orally active and allosteric JAK2 inhibitor, selectively inhibits JAK2 mediated phosphorylation and activation of EGFR (Tyr 1068) and STAT3 by binding to JAK2. G5-7 induces cell cycle arrest, apoptosis and possesses antiangiogenic effect. G5-7 has the potential for glioma study .
    G5-7
  • HY-N0005S
    Curcumin-d6

    Diferuloylmethane-d6; Natural Yellow 3-d6; Turmeric yellow-d6

    		 Isotope-Labeled Compounds Keap1-Nrf2 Ferroptosis Autophagy Histone Acetyltransferase Epigenetic Reader Domain Mitophagy Influenza Virus Infection Metabolic Disease Inflammation/Immunology Cancer
    Curcumin-d6 (Diferuloylmethane-d6 ) is deuterium labeled Curcumin (HY-N0005). Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin is a photosensitizer against microorganisms. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.
    Curcumin-d6
  • HY-133016
    M8891

    		MetAP Cardiovascular Disease Cancer
    M8891 is an orally active, reversible and brain penetrant Methionine Aminopeptidase-2 (MetAP-2) inhibitor with an IC50 of 54 nM and a Ki of 4.33 nM. M8891 does not inhibit MetAP-1 (IC50>10 µM) . M8891 inhibits growth of primary endothelial cells as well as tumor cells and demonstrates antiangiogenic and antitumoral activity .
    M8891
  • HY-B0639A
    Amifostine trihydrate
    10+ Cited Publications

    WR2721 trihydrate

    		 MDM-2/p53 HIF/HIF Prolyl-Hydroxylase Cancer
    Amifostine trihydrate (WR2721 trihydrate) is a broad-spectrum cytoprotective agent and a radioprotector. Amifostine trihydrate selectively protects normal tissues from damage caused by radiation and chemotherapy. Amifostine trihydrate is potent hypoxia-inducible factor-α1 (HIF-α1) and p53 inducer. Amifostine trihydrate protects cells from damage by scavenging oxygen-derived free radicals. Amifostine trihydrate reduces renal toxicity and has antiangiogenic action .
    Amifostine trihydrate
  • HY-N4094
    Morellic acid
    1 Publications Verification

    		 Others Inflammation/Immunology
    Morellic acid is isolated from Garcinia Morella with an antiangiogenic activity .
    Morellic acid
  • HY-120784
    Hexafluoro-diallylhexaflurobisphenol

    		Drug Derivative Others
    Hexafluoro-diallylhexaflurobisphenol is a Honokiol analogue (HA). Honokiol is a bioactive, biphenolic phytochemical that possesses potent antioxidative, anti-inflammatory, antiangiogenic, and anticancer activities by targeting a variety of signaling molecules .
    Hexafluoro-diallylhexaflurobisphenol
  • HY-113649
    AKB-6899
    2 Publications Verification

    		 HIF/HIF Prolyl-Hydroxylase Cancer
    AKB-6899, a prolyl hydroxylase domain 3 (PHD3) inhibitor, is a selective HIF-2α stabilizer. AKB-6899 also increases soluble form of the VEGF receptor (sVEGFR-1) production from GM-CSF-treated macrophages, and has antitumor and antiangiogenic effects .
    AKB-6899
  • HY-108486
    Herbimycin A

    		Bacterial Antibiotic Infection
    Herbimycin A, an ansamycin antibiotic, acts as a Src family kinase inhibitor. Herbimycin A binds to the SH domain and inhibits the activity of p60 v-src and p210 BCR-ABL Herbimycin A inhibits Hsp90 and impairs recovery from heat shock. Herbimycin A exhibits antiangiogenic activity in endothelial cells in vitro.
    Herbimycin A
  • HY-100450
    BML-111
    1 Publications Verification

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease Inflammation/Immunology Cancer
    BML-111, a lipoxin A4 analog, is a lipoxin A4 receptor agonist. BML-111 represses the activity of angiotensin converting enzyme (ACE) and increases the activity of angiotensinconverting enzyme 2 (ACE2). BML-111 has antiangiogenic, antitumor and anti-inflammatory properties .
    BML-111
  • HY-114785
    BPHA

    		MMP Cancer
    BPHA is a potent and orally active MMP-2, MMP-9 and MMP-14 inhibitor with IC50s of 12 nM, 16 nM and 17 nM, respectively. BPHA does not inhibit MMP-1, -3, and -7 (the IC50s are 974, >1000, and 795 nM, respectively). BPHA has antiangiogenic and antitumor effects .
    BPHA
  • HY-19754A
    CRA-026440 hydrochloride

    		HDAC Apoptosis Cancer
    CRA-026440 hydrochloride is a potent, broad-spectrum HDAC (HDAC) inhibitor. The Ki values against recombinant HDAC isoenzymes HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, and HDAC10 are 4 nM, 14 nM, 11 nM, 15 nM, 7 nM, and 20 nM respectively. CRA-026440 hydrochloride shows antitumor and antiangiogenic activities . CRA-026440 (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    CRA-026440 hydrochloride
  • HY-103387
    DuP-697
    1 Publications Verification

    		 COX Apoptosis Inflammation/Immunology Cancer
    DuP-697 is a member of the vicinal diaryl heterocycles and a potent, irreversible, selective and orally active COX-2 inhibitor (IC50 of 10 nM and 800 nM for human COX-2 and COX-1, respectively). DuP-697 exerts antiproliferative (IC50 of 42.8 nM), antiangiogenic and apoptotic effects on HT29 colorectal cancer cells. DuP-697 inhibits prostaglandin synthesis and has anti-inflammatory, anticancer and antipyretic effects .
    DuP-697
  • HY-P1615
    Cenupatide

    		Transmembrane Glycoprotein Cancer
    Cenupatide (UPARANT) is a Urokinase-type plasminogen activator receptor (uPAR) inhibitor. Cenupatide has anti-angiogenic and anti-inflammatory efficacy .
    Cenupatide
  • HY-P1415A
    Norleual TFA
    1 Publications Verification

    		 c-Met/HGFR Angiotensin Receptor Cardiovascular Disease Neurological Disease Metabolic Disease
    Norleual TFA, an angiotensin (Ang) IV analog, is a hepatocyte growth factor (HGF)/c-Met inhibitor with an IC50 of 3 pM. Norleual TFA is an AT4 receptor antagonist and exhibits potent antiangiogenic activities .
    Norleual TFA
  • HY-16958
    PD 404182
    1 Publications Verification

    		 Antibiotic Dimethylargininase (DDAH) Inflammation/Immunology
    PD 404182 is a potent and competitive inhibitor of human dimethylarginine dimethylaminohydrolase 1 (DDAH1), with an IC50 of 9 μM. PD 404182 exhibits antiangiogenic and antiviral activity in vitro .
    PD 404182
  • HY-114653
    SRPIN803

    		Casein Kinase SRPK Cancer
    SRPIN803 is a potent CK2 and SRPK1 dual inhibitor, with IC50s of 203 nM and 2.4 μM, respectively. SRPIN803 exhibits antiangiogenic activity. SRPIN803 can be used for the research of age-related macular degeneration .
    SRPIN803
  • HY-10517A
    (Z)-Orantinib

    (Z)-SU6668; (Z)-TSU-68

    		 VEGFR PDGFR FGFR Cancer
    (Z)-Orantinib ((Z)-SU6668) is a potent, selective, orally active and ATP competitive inhibitor of Flk‐1/KDR, PDGFRβ, and FGFR1, with IC50s of 2.1, 0.008, and 1.2 µM, respectively. (Z)-Orantinib is a potent antiangiogenic and antitumor agent that induces regression of established tumors .
    (Z)-Orantinib
  • HY-B0421R
    Mycophenolic acid (Standard)

    Mycophenolate (Standard)

    		 Dengue Virus Reference Standards Apoptosis Bacterial Fungal Endogenous Metabolite Antibiotic Flavivirus Infection Inflammation/Immunology Cancer
    Mycophenolic acid (Standard) is the analytical standard of Mycophenolic acid. This product is intended for research and analytical applications. Mycophenolic acid is a potent uncompetitive inosine monophosphate dehydrogenase (IMPDH) inhibitor with an EC50 of 0.24 μM.?Mycophenolic acid demonstrates antiviral effects against a wide range of RNA viruses including influenza. Mycophenolic acid is an immunosuppressive agent. Antiangiogenic and antitumor effects .
    Mycophenolic acid (Standard)
  • HY-17514R
    Itraconazole (Standard)

    R51211 (Standard)

    		 Reference Standards Fungal Hedgehog Cytochrome P450 Autophagy Antibiotic Bacterial Infection Cancer
    Itraconazole (Standard) is the analytical standard of Itraconazole. This product is intended for research and analytical applications. Itraconazole (R51211) is a triazole antifungal agent and a potent and orally active Hedgehog (Hh) signaling pathway antagonist with an IC50 of ~800 nM. Itraconazole potently inhibits lanosterol 14α-demethylase (cytochrome P450 enzyme), thereby inhibits the oxidative conversion of lanosterol to ergosterol. Itraconazole has anticancer and antiangiogenic effects. Itraconazole is a oxysterol-binding protein (OSBP) inhibitor .
    Itraconazole (Standard)
  • HY-13016R
    Cabozantinib (Standard)

    XL184 (Standard); BMS-907351 (Standard)

    		 Reference Standards VEGFR c-Met/HGFR c-Kit TAM Receptor FLT3 Apoptosis Cancer
    Cabozantinib (Standard) is the analytical standard of Cabozantinib. This product is intended for research and analytical applications. Cabozantinib is a potent and orally active inhibitor of VEGFR2 and MET, with IC50 values of 0.035, and 1.3 nM, respectively. Cabozantinib displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC50=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib shows antiangiogenic activity. Cabozantinib disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis .
    Cabozantinib (Standard)
  • HY-119425
    Razoxane

    ICRF 159

    		 Topoisomerase Cancer
    Razoxane (ICRF 159), a EDTA (HY-Y0682) derivative, is an orally active antiangiogenic topoisomerase II inhibitor. Razoxane has antineoplastic, antiangiogenic, and antimetastatic activities. Razoxanecan be used for the research of renal cell carcinoma (RCC), lung cancer and melanoma cancer .
    Razoxane
  • HY-119062
    A-800141

    		MetAP CDK Cancer
    A-800141 is an orally active, selective, sulfonamide-based MetAP2 inhibitor (IC50=12 nM) that binds reversibly to MetAP2 and interacts with its manganese ions. A-800141 induces the production of N-terminal methionine-unprocessed GAPDH variants, which in turn triggers G1-phase cell cycle arrest, elevates p21 levels, and reduces the levels of phosphorylated Rb and total cyclin A. A-800141 exhibits anti-angiogenic and tumor growth inhibitory effects, and produces synergistic effects when combined with cytotoxic inhibitors or BCL-2 inhibitors. A-800141 has been widely used in scientific research related to B-cell lymphoma, neuroblastoma, prostate cancer, colon cancer, melanoma and other fields .
    A-800141
  • HY-P5840
    Cyclo(RGDyC)

    		Biochemical Assay Reagents Cancer
    Cyclo(RGDyC) is a cyclic pentapeptide with anti-angiogenic abilities. Cyclo(RGDyC) can be combined with liposome delivery systems for research on ocular neovascular diseases and cancer .
    Cyclo(RGDyC)
  • HY-163475
    CXCL-CXCR1/2-IN-1
    1 Publications Verification

    		 CXCR Cancer
    CXCL-CXCR1/2-IN-1 is an orally active ELR +CXCL-CXCR1/2 pathway inhibitor with an EC50 of 42.7 nM for CXCR2 . CXCL-CXCR1/2-IN-1 shows anticancer and antiangiogenic effects .
    CXCL-CXCR1/2-IN-1
  • HY-146375
    UniPR505

    		Ephrin Receptor Cancer
    UniPR505 (Compound 14) is an EphA2 antagonist with an IC50 of 0.95 µM. UniPR505 displays anti-angiogenic properties .
    UniPR505
  • HY-133571
    Aminohexylgeldanamycin

    AHGDM

    		 HSP ADC Payload Cancer
    Aminohexylgeldanamycin (AHGDM), a Geldanamycin derivative, is a potent HSP90 inhibitor. Aminohexylgeldanamycin shows antiangiogenic and antitumor activities .
    Aminohexylgeldanamycin
  • HY-15198
    KG5

    		Raf PDGFR FLT3 c-Kit Cancer
    KG5 is an orally active dual PDGFRβ and B-Raf allosteric inhibitor. KG5 also inhibits Flt3, KIT and c-Raf. KG5 has anticancer, antiangiogenic activities .
    KG5

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: